Greenwich LifeSciences (NASDAQ:GLSI) Stock Falls 2.1% – Time to Sell?Defense World · Oct 4, 2026
20 stocks likely to lose money even if the bull market continuesMarket Watch · Aug 27, 2026
Greenwich LifeSciences Extends Lock-up of Directors and Officers to January 31, 2027GlobeNewsWire · Aug 10, 2026Greenwich LifeSciences, Inc. functions as a clinical-stage biopharmaceutical company, dedicated to developing innovative cancer immunotherapies. These treatments are primarily focused on breast cancer and other HER2/neu-positive malignancies. Its flagship therapeutic candidate is GP2, an immunotherapy which has successfully completed its Phase IIb clinical trials.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 11, 2026 | -$0.33 | -$0.27 | Beat |
| Jun 3, 2026 | -$0.33 | -$0.39 | Miss |
| Mar 31, 2026 | -$0.32 | -$0.32 | Beat |
| Nov 14, 2025 | -$0.30 | -$0.30 | Beat |
| Aug 14, 2025 | -$0.24 | -$0.30 | Miss |
| May 20, 2025 | -$0.24 | -$0.25 | Miss |